May 19, 2025 5:00 am EDT Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
May 13, 2025 7:00 am EDT Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
May 8, 2025 4:01 pm EDT Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
May 7, 2025 7:00 am EDT Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
Apr 15, 2025 7:00 am EDT Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model